Blog
EQS-News: Cryptology’s estimated NAV per share as of 07/12/2022 is €4.35
EQS-News: Cryptology’s estimated NAV per share as of 07/12/2022 is €4.35
EQS-News: BB BIOTECH AG: Molecular strike force for the immune system
EQS-News: BB BIOTECH AG: Molecular strike force for the immune system
EQS-Adhoc: SPORTTOTAL AG releases litigation provisions of around EUR 1.8 million
EQS-Adhoc: SPORTTOTAL AG releases litigation provisions of around EUR 1.8 million
Form 8.3 - Maitland Institutional Services Limited: Re In The Style Group PLC
Form 8.3 - Maitland Institutional Services Limited: Re In The Style Group PLC
Rights and Issues Investment Trust PLC: Directorate Change
Rights and Issues Investment Trust PLC: Directorate Change
Form 8.3 - The Vanguard Group, Inc.: HomeServe plc
Form 8.3 - The Vanguard Group, Inc.: HomeServe plc
EQS-News: publity AG: Changes in the Supervisory Board
EQS-News: publity AG: Changes in the Supervisory Board
Form 8.3 - The Vanguard Group, Inc.: AVEVA Group plc
Form 8.3 - The Vanguard Group, Inc.: AVEVA Group plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
EQS-News: Genius Metals Partners with Clarity Gold to Advance its Lithium381 Property in James Bay (QC)
EQS-News: Genius Metals Partners with Clarity Gold to Advance its Lithium381 Property in James Bay (QC)
Rights and Issues Investment Trust PLC: Net Asset Value(s)
Rights and Issues Investment Trust PLC: Net Asset Value(s)
Chelverton UK Dividend Trust plc: Net Asset Value(s)
Chelverton UK Dividend Trust plc: Net Asset Value(s)
EQS-News: Linde Achieves Industry-Leading Score in S&P Global Corporate Sustainability Assessment
EQS-News: Linde Achieves Industry-Leading Score in S&P Global Corporate Sustainability Assessment
EQS-News: clearvise AG creates further scope for portfolio expansion with successful capital increase
EQS-News: clearvise AG creates further scope for portfolio expansion with successful capital increase
Chelverton UK Dividend Trust plc: PDMR Shareholding
Chelverton UK Dividend Trust plc: PDMR Shareholding
EQS-News: Salzgitter Aktiengesellschaft: Salzgitter AG sells Salzgitter Bauelemente GmbH to FALK Bouwsystemen
EQS-News: Salzgitter Aktiengesellschaft: Salzgitter AG sells Salzgitter Bauelemente GmbH to FALK Bouwsystemen
Renewi plc: PDMR shareholding
Renewi plc: PDMR shareholding
EQS-News: PUMA SE: PUMA to appoint Maria Valdes as Chief Product Officer and Member of the Board of Management
EQS-News: PUMA SE: PUMA to appoint Maria Valdes as Chief Product Officer and Member of the Board of Management
EQS-News: GORE German Office Real Estate AG: Shareholders approve all agenda items at Annual General Meeting with large majorities
EQS-News: GORE German Office Real Estate AG: Shareholders approve all agenda items at Annual General Meeting with large majorities
EVRAZ plc announces results of the Consent Solicitation for its outstanding U.S.$750,000,000 5.375 per cent. notes due 2023
EVRAZ plc announces results of the Consent Solicitation for its outstanding U.S.$750,000,000 5.375 per cent. notes due 2023
NOTICE OF ADJOURNED MEETING to the holders of outstanding U.S.$700,000,000 5.250 per cent. notes due 2024 issued by the Issuer
NOTICE OF ADJOURNED MEETING to the holders of outstanding U.S.$700,000,000 5.250 per cent. notes due 2024 issued by the Issuer
EQS-News: Leading Global Brewery Group Migrates SAP Systems to Microsoft Azure Cloud with SNP
EQS-News: Leading Global Brewery Group Migrates SAP Systems to Microsoft Azure Cloud with SNP
EQS-Adhoc: clearvise AG successfully completes rights issue
EQS-Adhoc: clearvise AG successfully completes rights issue
EQS-News: 029 Group SE: NuWays by Hauck Aufhäuser Lampe initiates coverage of 029 Group with ‘Buy’ recommendation and price target of €14.20
EQS-News: 029 Group SE: NuWays by Hauck Aufhäuser Lampe initiates coverage of 029 Group with ‘Buy’ recommendation and price target of €14.20
Hardman & Co Research on International Biotechnology Trust (IBT): Low FDA activity may drive further M&A
Hardman & Co Research on International Biotechnology Trust (IBT): Low FDA activity may drive further M&A


